BioPerfectus (SSE: 688399) stands at the forefront of the molecular diagnostics industry, with a specialization in “diagnostics for infectious diseases and women’s and children’s health”. Founded in 2010, BioPerfectus consistently emphasizes R&D, manufacturing, and the distribution of in-vitro diagnostic reagents and instruments. Through strategic planning, the company has seamlessly integrated its efforts from the development and production of upstream core materials to downstream diagnostic services. With a diverse portfolio of over 600 products, BioPerfectus caters to a broad spectrum of medical institutions, CDCs, and independent clinical laboratories across more than 100 countries and regions. Further solidifying its position in molecular diagnostics, BioPerfectus proactively ventures into high-growth areas such as POCT (Point-of-Care Testing). The company’s strategic focus is on expanding applications, refining its product range, and making inroads into international markets. Guided by the vision “To be one of the top global IVD suppliers,”and driven by the mission of “For a healthier future,”BioPerfectus utilizes precise, effective, and streamlined diagnostic techniques with the aim of pioneering advanced early screening and diagnostic methods for infectious diseases and major health challenges, thereby enhancing the quality of life and championing global health.
From the very beginning, BioPerfectus has been committed to contributing to our nation through industry and to bringing benefits to society at large. Over the past decade, our company has concentrated on leading the charge in various disease areas, relentlessly pursuing innovation in diagnostic products, and consistently delivering value to patients, families, and healthcare professionals across the globe. Our active participation in major and emergent public health crises has further solidified our dedication to advancing the healthcare system and safeguarding the health of communities worldwide.
Despite the ongoing global health threats posed by infectious diseases and cancer, we are heartened to observe significant progress in combating these complex diseases, thanks to the collective efforts of medical institutions, industry experts, and multidisciplinary partners. Looking ahead, we are filled with passion and confidence, committing ourselves to be a trusted partner in smart testing and disease management for healthcare professionals. We are determined to address the ongoing diagnostic needs of patients and physicians, to contribute to the achievement of the "Healthy China 2030" strategic goals, and to invest our intelligence and energy in securing a healthier future for humanity.